The Director of Tissue Supply position is responsible for developing a network of human birth tissue recovery resources and assuring an influx of tissues to meet TissueTech current and future manufacturing needs. The incumbent is responsible for developing a strategic approach to tissue supply, identifying potential recovery resources, creating and presenting recovery programs to potential hospitals/healthcare systems/professional societies, as well as negotiating long-term supply agreements with tissue supply partners. The Director of Tissue Supply is the primary contact point within TissueTech for issues involving forecasts, contract issues, and functions as a subject matter expert that represents TissueTech’s interests in industry and trade groups and is responsible for managing internal resources that identify and collect human birth tissue at hospitals and other sites. This includes identifying target collection sites, developing support facilities, hiring staff and managing the performance of those teams.
Develop and execute a rolling 5-year strategic plan to provide an assured supply of human birth tissue capable of meeting TissueTech’s current and future manufacturing needs.
Represent TissueTech in meetings with third-party tissue recovery organizations, hospitals/healthcare networks, umbrella professional organizations such as AATB and medical professionals to gain access to tissue resources.
Understand market dynamics of birth tissue to assure that TissueTech is competitive in evolving market situations.
Develop and negotiate contracts to assure long-term access to birth tissues.
Hire, train and manage staff, as well as facilities to support collection of birth tissues. These staff members may be geographically dispersed across the United States and support local collection programs.
Coordinate development of quality and commercial requirements for tissue sourcing teams (internal and third party).
Prepare and present presentations to a wide variety of audiences detailing the reasons for donating birth tissue and the societal advantages of such donations.
Develop annual budgets and manage performance against those targets.
Provide direct supervision for staff within the tissue Supply teams. These teams may be geographically dispersed.
Review and oversee training and competencies for new and existing employees.
Gain consensus regarding performance metrics and assess results against those measures.
Responsible for the other duties and projects as assigned.
Education - Bachelor’s Degree in Biology, Chemistry, Engineering, Physical Science, business or related field.
Experience - 10 years of experience with a solid understanding of GMP, GLP, ISO, or Quality System experience. Prior tissue bank experience setting up and running tissue collection programs is essential. Experience with birth tissue is desired.
Industry experience in GMP/GTP environment, knowledge of aseptic technique and lab testing experience required
Ability to think strategically and act tactically to achieve business goals.
Excellent communication skills, with the ability to prepare materials for audiences of widely varying background and experience.
Keen observational skills and troubleshooting skills.
Excellent interpersonal skills and the ability to communicate both up and down the organization.
Fluent (oral/written) English.
Computer Proficiency—good computer skills with emphasis on MS Office products.
Internal Number: 220
About TissueTech Inc
TissueTech, Inc. is the leader in innovative technologies using products derived from human amniotic and umbilical cord tissues. Since its inception in 1997, the Company has pioneered the clinical application of human placental tissues – more than 300,000 patients have been treated with TissueTech products and the Company’s groundbreaking scientific and clinical achievements have been documented in more than 300 peer-reviewed publications.
TissueTech was founded in 2001 as the parent entity for Bio-Tissue Inc., which develops and markets regenerative therapies for treating the ocular surface. In 1997, Bio-Tissue was the first company to introduce the use of cryopreserved amniotic membrane tissue for clinical application, by utilizing its proprietary CryoTek technology, proven to preserve the innate biological and structural properties of the amniotic membrane tissue.
Initial research on the company’s proprietary technology began in 1986 and was led by the company’s –co-founder Scheffer C. G. Tseng, M.D., Ph.D., with a grant from the National Institutes of Health (NIH). Dr. Tseng spearheaded efforts in the scientific and clinical community to utilize the innate regenerative ...properties of human umbilical cord and amniotic membrane tissue to promote wound healing. Since then, the company has received 30 years of continuous National Institutes of Health (NIH) support to support ongoing scientific research. This groundbreaking research has led to the development of products at the forefront of innovation that are used by doctors around the world.
Today, Bio-Tissue leads the ophthalmic market providing the only tissue recognized by the U.S. Food and Drug Administration (FDA) to reduce inflammation and prevent scarring and angiogenesis of the ocular surface. In 2011, a second commercial entity, Amniox Medical, Inc. was founded to market the company’s proprietary technology in the orthopedic, wound care, and spine markets. In its short history, Amniox Medical has become a leader in these sectors.
TissueTech continues to receive recognition for its many accomplishments. In 2014, the company was recognized as one of the 5000 Fastest Growing Incorporated Private Companies in the United States. The Greater Miami Chamber of Commerce named its business unit Bio-Tissue Minority-Owned Business of the Year. In 2015, TissueTech was the recipient of the prestigious Tibbetts Award from the U.S. Small Business Administration (SBA) in recognition of its significant contributions to the field of regenerative medicine. In 2017, the Company received the award for Spine Technology Innovation in Biologics at the North American Spine Society annual meeting.